Localization by hand-held gamma probe of tumor labeled with antibody “cocktail”

Five groups ( n = 4) of congenitally athymic female nude mice bearing subcutaneous implants of CX-1 and/or SW-1116 tumor in the hind limbs received iodine-125 radio-labeled monoclonal antibodies (MoAbs) B72.3 (two groups), 17-1A (two groups), and cocktail (one group) (iodogen method, 50 μCi/10 μg/mo...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of surgical research Vol. 47; no. 3; pp. 227 - 234
Main Authors Sardi, Armando, Alam Siddiqi, M., Hinkle, George, Rousseau, Michel, Gersman, Mark, Hill, Tim, Olsen, John, Tuttle, Steven, Young, Donn, Houchens, David, Thurston, Marlin, Martin, Edward W.
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.09.1989
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Five groups ( n = 4) of congenitally athymic female nude mice bearing subcutaneous implants of CX-1 and/or SW-1116 tumor in the hind limbs received iodine-125 radio-labeled monoclonal antibodies (MoAbs) B72.3 (two groups), 17-1A (two groups), and cocktail (one group) (iodogen method, 50 μCi/10 μg/mouse). Daily probe counts were made in duplicate with a hand-held detector over each tumor site and the front leg (background) for 21 days. Animals were sacrificed and appropriate well counts were obtained. All the single MoAb preparations localized well in both tumor cell lines. Uptake of monoclonal antibody 17-1A was similar in the two tumor cell lines, with counts initially high and slowly decreasing over the 21-day period. Tumor/background ratios continued to increase over time, indicating that both tumor lines have similar antigenic expression for the monoclonal antibody 17-1A. This was not the case for monoclonal antibody B72.3, which showed a preferential uptake by the CX-1 tumor, with higher initial counts and prolonged binding of the antibody, giving rise to higher tumor/background ratios. The mixture of monoclonal antibodies B72.3 and 17-1A markedly improved the uptake by the CX-1 tumor cell line but not that by the SW-1116 cell line, where the effect was negative when compared to the uptake of the single MoAb preparations. The use of a monoclonal antibody mixture can enhance targeting of some tumor sites. Due to the heterogeneity of tumor cell lines, even within the same animal, different mixtures of monoclonal antibodies are needed to increase the targeting of tumor.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-4804
1095-8673
DOI:10.1016/0022-4804(89)90112-1